贝那利珠单抗可恢复重度哮喘中与类固醇敏感性相关的基因和微小RNA表达。 - Suppr | 超能文献

相似文献

1

Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma.贝那利珠单抗可恢复重度哮喘中与类固醇敏感性相关的基因和微小RNA表达。

Allergy. 2021 Aug;76(8):2589-2592. doi: 10.1111/all.14819. Epub 2021 May 10.

2

Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.抗IL-5Rα单克隆抗体贝那利珠单抗在未控制的嗜酸性粒细胞性哮喘中的疗效和安全性

Int Rev Immunol. 2016 Jul 3;35(4):294-311. doi: 10.3109/08830185.2015.1128901. Epub 2016 Apr 27.

3

Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.针对白细胞介素-5 信号通路的抗体作为严重嗜酸性粒细胞性哮喘患者的附加治疗药物：皮下给予美泊利珠单抗和贝那利珠单抗的作用机制、疗效和安全性的综述。

Expert Rev Respir Med. 2020 Apr;14(4):353-365. doi: 10.1080/17476348.2020.1718495. Epub 2020 Jan 23.

4

Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.贝那利珠单抗：一种用于治疗哮喘的抗白细胞介素-5受体α单克隆抗体。

Immunotherapy. 2018 Apr;10(5):349-359. doi: 10.2217/imt-2017-0161. Epub 2018 Jan 23.

5

Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with Benralizumab.在接受贝那利珠单抗治疗六个月前后，对重度哮喘合并鼻息肉患者的嗜酸性粒细胞性鼻炎症进行评估。

J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):2353-2357. doi: 10.23812/20-323-L.

6

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.血清 IgE 浓度预测重度嗜酸性粒细胞性哮喘患者恶化风险和 benralizumab 疗效的能力。

Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.

7

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.美泊利单抗、贝那利珠单抗和泼尼松龙治疗嗜酸性粒细胞性哮喘的血液嗜酸性粒细胞清除情况

Am J Respir Crit Care Med. 2020 Nov 1;202(9):1314-1316. doi: 10.1164/rccm.202003-0729LE.

8

Benralizumab for the treatment of asthma.贝那利珠单抗用于治疗哮喘。

Drugs Today (Barc). 2017 Dec;53(12):633-645. doi: 10.1358/dot.2017.53.12.2736670.

9

Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.贝那利珠单抗治疗哮喘的药代动力学/药效学药物评价

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):1007-1013. doi: 10.1080/17425255.2017.1359253. Epub 2017 Jul 24.

10

Benralizumab in Real Life.倍那利珠单抗的真实应用情况

J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):87-88. doi: 10.18176/jiaci.0599. Epub 2020 Jun 23.

引用本文的文献

1

PI3K pathway activation in severe asthma is linked to steroid insensitivity and adverse outcomes.重度哮喘中PI3K信号通路的激活与激素不敏感及不良预后相关。

J Allergy Clin Immunol Glob. 2025 Feb 12;4(2):100439. doi: 10.1016/j.jacig.2025.100439. eCollection 2025 May.

2

miRNAs as Modern Biomarkers in Asthma Therapy.miRNAs 作为哮喘治疗中的现代生物标志物。

Int J Mol Sci. 2023 Jul 15;24(14):11499. doi: 10.3390/ijms241411499.

3

Inadequate therapeutic responses to glucocorticoid treatment in bronchial asthma.支气管哮喘对糖皮质激素治疗反应不足。